CAMBRIDGE, Mass., Dec. 19 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) today announced that Bob Hamm has been appointed
Senior Vice President of North American Commercial Operations. In this newly
created position, Mr. Hamm will oversee Biogen's U.S. Neurology Business Unit,
U.S. Dermatology Business Unit, U.S. Commercial Services, and Canadian
Operations.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Mr. Hamm, who will report to Hans Peter Hasler, Executive Vice President,
Commercial Operations, will commence his new duties effective January 1, 2003.
"We are very pleased to have Bob Hamm lead our North American Commercial
Operations," said Mr. Hasler. "As Biogen transitions to a multi-product
biotechnology company, Bob's industry experience, strategic thinking, and
leadership abilities will play a critical role in growing our business."
Mr. Hamm joined Biogen in 1994 as Associate Director, Logistics. In that
position, he established Biogen's supply chain and played a major role in the
company's transformation from a research organization to an operating company
in 1996. Following an assignment in Europe from 1996 to 1999, Mr. Hamm was
named Vice President of Manufacturing and Engineering for Biogen. In 2001, he
was appointed head of Sales and Marketing of North America. In 2002, Mr. Hamm
was appointed Senior Vice President for Europe, Canada, and the Middle East.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and worldwide sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products.
Biogen's research and development activities are focused on novel products to
treat inflammatory and autoimmune diseases, neurological diseases, cancer,
fibrosis and congestive heart failure. The Company maintains active clinical
research programs in protein therapeutics, small molecules, genomics and gene
therapy. For copies of press releases and additional information about the
Company, please consult Biogen's Homepage on the World Wide Web at
http://www.Biogen.com
Media Contact:
Tim Hunt
Director, Public Affairs
Biogen, Inc.
Tel: (617) 914-6524
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
Tel: (617) 679-2812
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
CONTACT:
Tim Hunt, Director, Public Affairs,
+1-617-914-6524, or Christina Dillon, Manager, Investor Relations
+1-617-679-2812, both of Biogen, Inc.
|
